644784
Alternative Names: GW 644784Latest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain; Schizophrenia
Most Recent Events
- 20 Jan 2004 Phase-I clinical trials in Pain in United Kingdom (unspecified route)
- 20 Jan 2004 Phase-I clinical trials in Schizophrenia in United Kingdom (unspecified route)